225 related articles for article (PubMed ID: 25407255)
1. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Murphy J; Curtin C; Mamidi RN; Weiner S; Wang SS; Ariyawansa J; Stieltjes H; Wajs E; Di Prospero NA; Rothenberg P
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):115-28. PubMed ID: 25407255
[TBL] [Abstract][Full Text] [Related]
2. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
[TBL] [Abstract][Full Text] [Related]
3. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
Devineni D; Polidori D
Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Devineni D; Polidori D; Curtin CR; Murphy J; Wang SS; Stieltjes H; Wajs E
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):438-46. PubMed ID: 25907176
[TBL] [Abstract][Full Text] [Related]
6. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Stieltjes H; Wajs E
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):129-38. PubMed ID: 25500487
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
8. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
[TBL] [Abstract][Full Text] [Related]
10. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nyirjesy P; Zhao Y; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
[TBL] [Abstract][Full Text] [Related]
13. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
14. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
15. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
[TBL] [Abstract][Full Text] [Related]
16. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
[TBL] [Abstract][Full Text] [Related]
17. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
Devineni D; Manitpisitkul P; Murphy J; Stieltjes H; Ariyawansa J; Di Prospero NA; Rothenberg P
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):279-86. PubMed ID: 27136908
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Stein P; Berg JK; Morrow L; Polidori D; Artis E; Rusch S; Vaccaro N; Devineni D
Metabolism; 2014 Oct; 63(10):1296-303. PubMed ID: 25110280
[TBL] [Abstract][Full Text] [Related]
19. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Usiskin K; Kline I; Fung A; Mayer C; Meininger G
Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
